Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 2

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

NCT07225829 · View on ClinicalTrials.gov ↗

Study Summary

This phase 2a trial is an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of one single intra-articular (IA) injection of 4P004 or placebo in: * patients between 40 and 80 years of age, * with synovitis and grade 2 to 4 osteoarthritis (OA) of the knee according to Kellgren and Lawrence (KL) classification.

Interventions

  • DRUG 4P004
  • DRUG Placebo (NaCl 0.9%)

Study Locations (20)

Other

  • Durham Bone and Joint Specialists — Ajax
  • SJHC London Rheumatology Centre — London
  • G.R.M.O. (Groupe de recherche en maladies osseuses) Inc — Québec
  • Parker Institute Bispebjerg, Frederiksberg Hospital — Frederiksberg
  • Sanos Clinic Herlev — Herlev
  • CHU Montpellier — Montpellier
  • ChU de Nice — Nice
  • Hôpital Cochin — Paris
  • Hôpital Lariboisière — Paris
  • Centre Hospitalier Universitaire CHU de Reims - Hopital Maison Blanche — Reims
  • Care Access Kraków — Krakow
  • Centrum Medyczne Reuma Park — Warsaw
  • MICS Centrum Medyczne Warszawa — Warsaw
  • Complejo Hospitalario Universitario de A Coruna - Hospital Universitario de A Coruna — A Coruña
  • HLA Clínica Vistahermosa — Alicante
  • Corporacio Sanitaria Parc Tauli - Hospital de Sabadell — Sabadell
  • Hospital Universitario Marques de Valdecilla — Santander
  • Clinica Nuestra Senora de la Esperanza — Santiago de Compostela

Illinois

  • Northwestern University Feinberg School of Medicine — Chicago

Massachusetts

  • Skylight Health Research Burlington — Burlington

Trial Details

FieldValue
Enrollment Target 129 participants
Start Date 2025-06-17
Est. Completion 2026-05
Phase Phase 2

Sponsor

4Moving Biotech

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07225829

The ClinicalTrials.gov registry entry for NCT07225829 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 4Moving Biotech, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Knee Osteoarthritis appearing as the primary indexed condition, and to 2 interventions — of which 4P004 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07225829 reports 20 study locations spanning 3 distinct geographic areas — top geographies include Other, Illinois, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07225829 about?

NCT07225829 is a clinical study titled "A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis". This phase 2a trial is an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of one single intra-articular (IA) injection of 4P004 or placebo in: * patients between 40 and 80 years of age, * with synovitis and grade 2 to 4 osteoarth...

What is the current status of trial NCT07225829?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2025-06-17. Estimated completion is 2026-05.

What conditions does trial NCT07225829 study?

This clinical trial studies the following conditions: Knee Osteoarthritis, Synovitis of Knee. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07225829?

The interventions under investigation include: 4P004 (DRUG), Placebo (NaCl 0.9%) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07225829?

This trial is sponsored by 4Moving Biotech, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07225829 being conducted?

This trial has 20 study locations across Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial